Charles Schwab
ABUS icon

Charles Schwab’s Arbutus Biopharma ABUS Stock Holding History

Charles Schwab’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.87M Buy
1,431,218
+30,061
+2% +$132K ﹤0.01% 2325
2026
Q1 		$6.31M Sell
1,401,157
-161,108
-10% -$704K ﹤0.01% 2303
2025
Q4 		$7.51M Buy
1,562,265
+287,432
+23% +$1.29M ﹤0.01% 2265
2025
Q3 		$5.79M Buy
1,274,833
+21,004
+2% +$77.1K ﹤0.01% 2372
2025
Q2 		$3.87M Buy
1,253,829
+31,764
+3% +$105K ﹤0.01% 2437
2025
Q1 		$4.27M Sell
1,222,065
-136
-0% -$454 ﹤0.01% 2332
2024
Q4 		$4M Buy
1,222,201
+9,955
+0.8% +$36.6K ﹤0.01% 2439
2024
Q3 		$4.67M Buy
1,212,246
+831,663
+219% +$3.19M ﹤0.01% 2407
2024
Q2 		$1.18M Buy
380,583
+41,368
+12% +$124K ﹤0.01% 2864
2024
Q1 		$875K Sell
339,215
-10,143
-3% -$26.3K ﹤0.01% 2836
2023
Q4 		$873K Hold
349,358
– – ﹤0.01% 2878
2023
Q3 		$709K Buy
349,358
+13,285
+4% +$27.9K ﹤0.01% 2917
2023
Q2 		$773K Buy
336,073
+27,104
+9% +$70.5K ﹤0.01% 2859
2023
Q1 		$936K Buy
308,969
+3,689
+1% +$10.4K ﹤0.01% 2755
2022
Q4 		$711K Buy
305,280
+17,861
+6% +$42.7K ﹤0.01% 2894
2022
Q3 		$549K Sell
287,419
-535
-0.2% -$1.26K ﹤0.01% 2978
2022
Q2 		$781K Buy
287,954
+48,241
+20% +$123K ﹤0.01% 2888
2022
Q1 		$715K Buy
239,713
+30,338
+14% +$92.9K ﹤0.01% 2983
2021
Q4 		$815K Hold
209,375
– – ﹤0.01% 2984
2021
Q3 		$899K Buy
209,375
+22,907
+12% +$76.3K ﹤0.01% 2914
2021
Q2 		$565K Buy
186,468
+165,556
+792% +$513K ﹤0.01% 3127
2021
Q1 		$70K Hold
20,912
– – ﹤0.01% 3411
2020
Q4 		$75K Sell
20,912
-12,000
-36% -$42K ﹤0.01% 3334
2020
Q3 		$104K Buy
+32,912
New +$100K ﹤0.01% 3248
2019
Q2 		– Sell
-65,900
Closed -$236K – 3213
2019
Q1 		$236K Hold
65,900
– – ﹤0.01% 2992
2018
Q4 		$253K Hold
65,900
– – ﹤0.01% 2979
2018
Q3 		$623K Hold
65,900
– – ﹤0.01% 2766
2018
Q2 		$482K Buy
+65,900
New +$392K ﹤0.01% 2816

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Charles Schwab's ABUS Position: Q2 2026 in Review

Charles Schwab increased its Arbutus Biopharma (ABUS) stake by 2.1% in Q2 2026, buying an estimated $132K and bringing the position to 1,431,218 shares worth $6.87M. The position accounts for ﹤0.01% of the portfolio, ranked #2325.

Charles Schwab first reported a position in ABUS in Q2 2018 and has held it in 28 quarters since. The position peaked at $7.51M in Q4 2025. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Charles Schwab held 1,431,218 shares of Arbutus Biopharma worth $6.87M as of Q2 2026.
  • Charles Schwab bought 30,061 Arbutus Biopharma shares in Q2 2026, an estimated $132K.
  • Arbutus Biopharma made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2325 holding.
  • Charles Schwab first reported a position in Arbutus Biopharma in Q2 2018 and has held it in 28 quarters since.
  • Charles Schwab's Arbutus Biopharma position peaked at $7.51M in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.